Brief: REGENXBIO Announces Completion Of Pivotal Enrollment And Initiates Commercial Production In Duchenne Gene Therapy Program
30/10/2025 11:07
Oct 30 (Reuters) - Regenxbio Inc RGNX.O: REGENXBIO ANNOUNCES COMPLETION OF PIVOTAL ENROLLMENT AND INITIATES COMMERCIAL PRODUCTION IN DUCHENNE GENE THERAPY PROGRAM REGENXBIO INC - TOPLINE PIVOTAL DATA EXPECTED EARLY Q2 2026, BLA SUBMISSION MID-2026 Source text: ID:nPn4091Rra Further company coverage: RGNX.O
Recent news on REGENXBIO
See all newsBrief: Regenxbio says Sarepta To Pay $39 Million To Regenxbio Within 10 Days Of Effective Date
Regenxbio climbs as new director buys nearly $1 million of stock
Brief: Regenxbio Strengthens Board Of Directors With Appointment Of Greg Ciongoli
U.S. STOCKS ON THE MOVE-Strategy, Ecovyst, Azenta
U.S. STOCKS ON THE MOVE-Azenta, Qiagen NV, Capricor Therapeutics